Addex Therapeutics Ltd (ADXN)

Market Cap	6.64M
Revenue (ttm)	960,641
Net Income (ttm)	4.80M
Shares Out	98.30M
EPS (ttm)	0.05
PE Ratio	1.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,931
Open	7.82
Previous Close	7.97
Day's Range	7.34 - 7.82
52-Week Range	5.00 - 27.90
Beta	1.87
Analysts	Strong Buy
Price Target	30.00 (+306.5%)
Earnings Date	Nov 22, 2024

About ADXN

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: ADXN
• Website: https://www.addextherapeutics.com

Financial Performance

In 2023, Addex Therapeutics's revenue was 1.65 million, an increase of 13.99% compared to the previous year's 1.44 million. Losses were -10.56 million, -49.26% less than in 2022.

Financial numbers in CHF

Analyst Forecast

According to one analyst, the rating for ADXN stock is "Strong Buy" and the 12-month stock price forecast is $30.0.

Price Target

$30.0

(306.50% upside)

Analyst Consensus: Strong Buy